Pacific Biosciences of California PACB Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's change in deferred revenue?
- Pacific Biosciences of California (PACB) reported change in deferred revenue of $19K in Q1 2026.
- How has Pacific Biosciences of California's change in deferred revenue changed year-over-year?
- Pacific Biosciences of California's change in deferred revenue decreased by 98.6% year-over-year, from $1.33M to $19K.
- What is the long-term trend for Pacific Biosciences of California's change in deferred revenue?
- Over 2 years (2022 to 2024), Pacific Biosciences of California's change in deferred revenue has grown at a -24.9% compound annual growth rate (CAGR), from -$3.73M to -$2.11M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.